See more : VBG Group AB (publ) (VBG-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Inovio Pharmaceuticals, Inc. (INO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inovio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Monster Beverage Corporation (0K34.L) Income Statement Analysis – Financial Results
- PT RMK Energy Tbk (RMKE.JK) Income Statement Analysis – Financial Results
- Fritzy Tech Inc. (FRFR) Income Statement Analysis – Financial Results
- Dragon Rise Group Holdings Limited (6829.HK) Income Statement Analysis – Financial Results
- Zhongliang Holdings Group Company Limited (2772.HK) Income Statement Analysis – Financial Results
Inovio Pharmaceuticals, Inc. (INO)
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 832.01K | 10.26M | 1.77M | 7.41M | 4.11M | 30.48M | 42.22M | 35.37M | 40.57M | 10.46M | 13.47M | 4.12M | 9.80M | 6.14M | 9.12M | 2.10M | 4.81M | 3.47M | 5.47M | 1.17M | 80.53K | 189.52K | 4.45M | 5.08M | 8.30M |
| Cost of Revenue | 3.50M | 5.50M | 4.73M | 94.25M | 88.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 225.00K | 206.25K | 0.00 | 0.00 | 0.00 | 1.93M | 1.46M | 1.20M |
| Gross Profit | -2.67M | 4.77M | -2.96M | -86.83M | -83.91M | 30.48M | 42.22M | 35.37M | 40.57M | 10.46M | 13.47M | 4.12M | 9.80M | 6.14M | 9.12M | 2.10M | 4.81M | 3.24M | 5.26M | 1.17M | 80.53K | 189.52K | 2.53M | 3.62M | 7.10M |
| Gross Profit Ratio | -321.09% | 46.44% | -166.56% | -1,171.66% | -2,040.54% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 93.51% | 96.23% | 100.00% | 100.00% | 100.00% | 56.77% | 71.29% | 85.54% |
| Research & Development | 86.68M | 187.65M | 249.24M | 94.25M | 88.02M | 95.26M | 98.57M | 88.71M | 57.79M | 34.10M | 21.37M | 17.98M | 20.03M | 13.26M | 9.41M | 5.75M | 9.63M | 8.51M | 11.45M | 6.55M | 2.15M | 2.47M | 459.71K | 6.98M | 8.10M |
| General & Administrative | 47.58M | 90.19M | 53.75M | 37.25M | 27.20M | 29.32M | 28.29M | 23.89M | 18.06M | 15.86M | 13.64M | 10.78M | 11.99M | 12.11M | 13.67M | 10.01M | 11.08M | 8.08M | 5.98M | 6.13M | 4.57M | 3.66M | 0.00 | 5.61M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.58M | 90.19M | 53.75M | 37.25M | 27.20M | 29.32M | 28.29M | 23.89M | 18.06M | 15.86M | 13.64M | 10.78M | 11.99M | 12.11M | 13.67M | 10.01M | 11.08M | 8.08M | 5.98M | 6.13M | 4.57M | 3.66M | 6.62M | 5.61M | 5.50M |
| Other Expenses | -1.70M | -3.86M | 343.37K | 3.42M | 496.20K | 360.80K | 806.82K | 127.55K | 177.56K | 348.14K | -45.63M | 1.98M | 0.00 | 0.00 | 9.28M | 4,672.53B | 7,547.58B | 225.00K | 206.25K | 5.60M | 2.07M | 2.28M | 0.00 | 566.36K | 400.00K |
| Operating Expenses | 132.56M | 277.84M | 302.99M | 131.49M | 115.22M | 124.57M | 126.86M | 112.60M | 75.86M | 49.95M | 35.01M | 28.76M | 32.02M | 25.36M | 23.08M | 15.76M | 20.71M | 16.81M | 17.64M | 12.68M | 6.71M | 6.12M | 7.08M | 13.15M | 14.00M |
| Cost & Expenses | 144.77M | 277.84M | 302.99M | 131.49M | 115.22M | 124.57M | 126.86M | 112.60M | 75.86M | 49.95M | 35.01M | 28.76M | 32.02M | 25.36M | 23.08M | 15.76M | 20.71M | 16.81M | 17.64M | 12.68M | 6.71M | 6.12M | 9.01M | 14.61M | 15.20M |
| Interest Income | 8.13M | 4.78M | 3.36M | 3.31M | 2.61M | 2.26M | 1.61M | 1.40M | 305.07K | 0.00 | 132.21K | 166.11K | 0.00 | 0.00 | 0.00 | 0.00 | 1.27M | 867.07K | 207.68K | 247.56K | 65.50K | 32.32K | 443.63K | 556.19K | 556.19K |
| Interest Expense | 1.22M | 1.25M | 1.94M | 8.70M | 7.95M | 346.09K | 4.56M | 139.25K | 0.00 | 0.00 | 88.17M | 0.00 | 34.29K | 0.00 | 10.50M | 0.00 | 0.00 | 0.00 | 3.33M | 0.00 | 20.48K | 5.45K | -20.38K | 24.34K | 24.34K |
| Depreciation & Amortization | 3.50M | 5.50M | 4.73M | 4.63M | 5.52M | 5.00M | 3.47M | 3.09M | 1.92M | 1.57M | 2.10M | 1.99M | 2.01M | 2.11M | 1.68M | 993.03K | 954.64K | 911.64K | 799.32K | 573.04K | 584.41K | 619.34K | 0.00 | 566.36K | 400.00K |
| EBITDA | -130.39M | -270.90M | -296.56M | -149.56M | -107.34M | -89.80M | -84.74M | -74.15M | -33.37M | -37.93M | -19.45M | -22.65M | -21.64M | -17.11M | -13.96M | -11.97M | -10.19M | -12.43M | -11.38M | -10.94M | -6.05M | -5.28M | -5.58M | -8.37M | -8.97M |
| EBITDA Ratio | -15,671.81% | -2,616.89% | -16,528.13% | -1,027.76% | -2,567.66% | -293.47% | -196.54% | -212.84% | -85.14% | -366.03% | 179.60% | -626.01% | -301.08% | -318.79% | -120.85% | -606.13% | -382.00% | -358.53% | -147.17% | -937.17% | -7,511.39% | -2,787.69% | -125.22% | -164.87% | -81.93% |
| Operating Income | -135.23M | -267.57M | -301.22M | -124.08M | -111.11M | -94.09M | -83.64M | -76.24M | -34.28M | -39.50M | -19.54M | -23.49M | -21.64M | -19.22M | -13.96M | -13.66M | -15.90M | -13.35M | -15.51M | -11.51M | -6.63M | -5.93M | -5.58M | -9.53M | -6.90M |
| Operating Income Ratio | -16,253.01% | -2,607.35% | -16,972.34% | -1,674.25% | -2,702.10% | -308.68% | -198.11% | -215.55% | -84.50% | -377.71% | -145.12% | -570.42% | -220.91% | -312.79% | -153.04% | -651.14% | -330.68% | -384.82% | -283.63% | -986.27% | -8,237.11% | -3,131.53% | -125.22% | -187.79% | -83.13% |
| Total Other Income/Expenses | 109.31K | -10.08M | -2.01M | -38.81M | -9.70M | -706.88K | -4.56M | 2.50M | 3.08M | 3.36M | -46.54M | 3.78M | 6.33M | 1.51M | -10.50M | 692.84K | 3.42M | 867.07K | 2.44K | 247.56K | 6.63M | 26.87K | -3.29M | -597.18K | 2.93M |
| Income Before Tax | -135.12M | -277.65M | -303.22M | -162.89M | -120.81M | -94.80M | -88.21M | -73.74M | -31.20M | -36.14M | -66.08M | -19.71M | -12.95M | -17.71M | -24.46M | -13.61M | -12.48M | -14.48M | -15.50M | -0.66 | -0.43 | -5.91M | -8.87M | -10.13M | -6.60M |
| Income Before Tax Ratio | -16,239.87% | -2,705.57% | -17,085.39% | -2,197.89% | -2,938.01% | -311.00% | -208.92% | -208.49% | -76.90% | -345.61% | -490.69% | -478.63% | -132.19% | -288.27% | -268.21% | -648.80% | -259.52% | -417.65% | -283.59% | 0.00% | 0.00% | -3,117.36% | -199.11% | -199.55% | -79.52% |
| Income Tax Expense | 0.00 | 10.01M | 2.16M | 52.20M | -257.34K | 2.17M | 1.76M | -4.62M | -2.10M | -3.72M | 88.12M | -8.11M | -16.28M | -4.08M | 11.71M | -741.85K | -8.12M | -867.07K | 6.45M | -537.76K | -1.99M | 56.78K | 0.00 | 638.17K | -600.00K |
| Net Income | -135.12M | -287.66M | -305.38M | -215.09M | -120.55M | -96.97M | -88.21M | -73.74M | -29.19M | -36.12M | -66.03M | -19.67M | -15.25M | -17.61M | -24.41M | -12.97M | -11.20M | -12.48M | -15.30M | -10.97M | -4.66M | -5.96M | -8.87M | -9.60M | -6.60M |
| Net Income Ratio | -16,239.87% | -2,803.13% | -17,207.13% | -2,902.17% | -2,931.76% | -318.12% | -208.92% | -208.49% | -71.94% | -345.44% | -490.29% | -477.56% | -155.72% | -286.65% | -267.67% | -618.11% | -233.05% | -359.82% | -279.79% | -940.19% | -5,792.83% | -3,147.32% | -199.11% | -189.07% | -79.52% |
| EPS | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 | -1.08 | -1.01 | -0.43 | -0.61 | -1.43 | -0.58 | -0.48 | -0.68 | -1.31 | -1.18 | -1.08 | -1.58 | -3.22 | -2.49 | -1.40 | -2.35 | -5.13 | -6.80 | -5.21 |
| EPS Diluted | -6.09 | -14.47 | -17.55 | -16.64 | -14.65 | -1.05 | -1.08 | -1.01 | -0.43 | -0.61 | -1.43 | -0.58 | -0.48 | -0.68 | -1.31 | -1.18 | -1.08 | -1.58 | -3.22 | -2.49 | -1.40 | -2.35 | -5.13 | -6.80 | -5.21 |
| Weighted Avg Shares Out | 22.17M | 19.89M | 17.40M | 12.93M | 8.23M | 92.35M | 81.78M | 73.01M | 68.20M | 59.13M | 46.09M | 33.91M | 31.56M | 25.80M | 18.68M | 10.98M | 10.37M | 7.88M | 4.75M | 4.41M | 3.33M | 2.54M | 1.73M | 1.41M | 1.27M |
| Weighted Avg Shares Out (Dil) | 22.17M | 19.89M | 17.40M | 12.93M | 8.23M | 92.54M | 81.92M | 73.21M | 68.37M | 59.41M | 46.09M | 34.13M | 31.56M | 25.80M | 18.68M | 10.98M | 10.37M | 7.88M | 4.75M | 4.41M | 3.33M | 2.54M | 1.73M | 1.41M | 1.27M |
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
INOVIO Reports Inducement Grant Under Inducement Plan
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
INOVIO to Present at Upcoming Scientific Conferences
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
Source: https://incomestatements.info
Category: Stock Reports